User profiles for Mubark Al-Mansour

mubarak al mansour

md
Verified email at ngha.med.sa
Cited by 1145

The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis

EM Ibrahim, ME Al-Foheidi, MM Al-Mansour… - Breast cancer research …, 2014 - Springer
In a recent meta-analysis, we demonstrated that rich tumor-infiltrating lymphocytes (TILs)
were significantly correlated to a favorable breast cancer (BC) outcome largely in estrogen …

[HTML][HTML] Energy and caloric restriction, and fasting and cancer: a narrative review

EM Ibrahim, MH Al-Foheidi, MM Al-Mansour - Supportive Care in Cancer, 2021 - Springer
Dietary interventions have a significant impact on body metabolism. The sensitivity of
cancer cells to nutrient and energy deficiency is an evolving characteristic of cancer biology. …

Breast cancer screening: review of benefits and harms, and recommendations for developing and low-income countries

M Al-Foheidi, MM Al-Mansour, EM Ibrahim - Medical oncology, 2013 - Springer
Breast cancer is the most common cancer in women worldwide. The disease remains a public
health concern as recent evidence indicates that the breast cancer burden has increased …

Transformation to aggressive lymphoma in nodular lymphocyte-predominant Hodgkin's lymphoma

M Al-Mansour, JM Connors, RD Gascoyne… - Journal of Clinical …, 2010 - ascopubs.org
Purpose Prior observations suggest a higher risk of transformation of nodular lymphocyte-predominant
Hodgkin's lymphoma (NLPHL) to aggressive lymphoma, most commonly diffuse …

Treating limited-stage nodular lymphocyte predominant Hodgkin lymphoma similarly to classical Hodgkin lymphoma with ABVD may improve outcome

KJ Savage, B Skinnider, M Al-Mansour… - Blood, The Journal …, 2011 - ashpublications.org
The appropriate therapy for limited-stage nodular lymphocyte predominant Hodgkin lymphoma
(NLPHL) is unclear. In contrast to classical Hodgkin lymphoma (CHL), chemotherapy is …

Advanced-stage nodular lymphocyte predominant Hodgkin lymphoma compared with classical Hodgkin lymphoma: a matched pair outcome analysis

…, JM Connors, A Lai, M Al-Mansour… - Blood, The Journal …, 2014 - ashpublications.org
Due to disease rarity, there is limited information regarding the optimal therapy and outcome
for patients with advanced-stage nodular lymphocyte-predominant Hodgkin lymphoma (…

[PDF][PDF] Three-dimensional virtual reality as an innovative teaching and learning tool for human anatomy courses in medical education: a mixed methods study

Y Alharbi, M Al-Mansour, R Al-Saffar, A Garman… - Cureus, 2020 - cureus.com
Poor knowledge retention is one reason for medical student attrition in learning and has
been a huge concern in medical education. Three-dimensional virtual reality (3D-VR)-based …

[HTML][HTML] Efficacy and safety of second‑generation CAR T‑cell therapy in diffuse large B‑cell lymphoma: A meta‑analysis

M AlMansour, M Al‑Foheidi… - Molecular and …, 2020 - spandidos-publications.com
Diffuse large B‑cell lymphoma (DLBCL) is the most common subtype of non‑Hodgkin's
lymphoma (NHL), representing 30% of all lymphoma cases. Within the first 2‑3 years following …

[HTML][HTML] Evaluation of problem-based learning in college of medicine: An indicator of quality education in a hybrid curriculum

SS Abed, M Al-Mansour, SN Ahmed… - Education Research …, 2023 - hindawi.com
Background. A culture of quality is believed to drive institutes toward excellence through
feedback. Multiple surveys at educational institute help to get a deeper insight into institutional …

[HTML][HTML] Treatment landscape of relapsed/refractory mantle cell lymphoma: an updated review

M Al-Mansour - Clinical Lymphoma Myeloma and Leukemia, 2022 - Elsevier
Mantle cell lymphoma (MCL) accounts for nearly 2-6% of all non-Hodgkin lymphoma (NHL)
cases, with a steady incidence increase over the past few decades. Although many patients …